Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| INBX | CLUSTER | bullish | 5/10 | Inhibrx Biosciences (INBX) insider cluster shows a director (Kayyem) making a $500K open-market purchase at $100/share, | Sep 17, 2026 |
| PHVS | 144 | bearish | 5/10 | Berndt Modig, an officer and director of Pharvaris N.V., filed a Form 144 notice of intent to sell up to 300,000 common | Sep 17, 2026 |
| HALO | CLUSTER | neutral | 2/10 | CEO Helen Torley exercised 20,000 options at $18.41 and immediately sold 20,000 shares on the open market at ~$107.15, n | Sep 17, 2026 |
| MEOH | SC 13G/A | neutral | 3/10 | Sunil Jagwani and Key Group Long Term Investments LP filed Amendment No. 3 to their Schedule 13G, reporting beneficial o | Sep 17, 2026 |
| SION | 144 | bearish | 5/10 | RA Capital Healthcare Fund LP, a 10% stockholder of Sionna Therapeutics, filed a Form 144 on September 17, 2026, indicat | Sep 17, 2026 |
| TPST | 8-K | bullish | 6/10 | Tempest Therapeutics entered into an exclusive option agreement with Hebei Senlang Biotechnology to license Senlang's CD | Sep 17, 2026 |
| HELP | 3 | neutral | 2/10 | Michael Halstead, CEO of Cybin Inc., filed an initial statement of beneficial ownership (Form 3) upon becoming an inside | Sep 17, 2026 |
| HURA | 8-K | neutral | 2/10 | TuHURA Biosciences drew down an additional $650,000 from its existing $50 million revolving credit facility with Parkvie | Sep 17, 2026 |
| CLDI | 424B5 | bearish | 6/10 | Calidi Biotherapeutics is issuing 1,025,640 shares of common stock at $1.17 per share in a direct offering to accredited | Sep 17, 2026 |
| YARW | SC 13G | neutral | 3/10 | Invus Global Management, LLC and affiliated entities filed a Schedule 13G disclosing passive beneficial ownership of 675 | Sep 17, 2026 |
| PULM | S-4/A | neutral | 5/10 | Pulmatrix, Inc. filed Amendment No. 3 to its S-4 registration statement, detailing the proposed reverse merger with Eos | Sep 17, 2026 |
| BIIB | PRESS-RELEASE | bullish | 5/10 | Biogen published positive adolescent subgroup results from the Phase 3 VALIANT study of EMPAVELI in C3G and primary IC-M | Sep 17, 2026 |
| RARE | PRESS-RELEASE | bullish | 8/10 | Ultragenyx announced FDA approval of FAYUVI (UX-101) as the first-ever treatment for Sanfilippo syndrome Type A (MPS III | Sep 17, 2026 |
| QNTM | 6-K | neutral | 4/10 | Quantum BioPharma filed a 6-K compiling press releases from March 2025 through August 2026, including its FY2025 audited | Sep 17, 2026 |
| PHVS | CLUSTER | bearish | 5/10 | Six Pharvaris insiders, including the CEO, President, and CCO, sold a total of ~$4.13M in open-market shares over a one- | Sep 17, 2026 |
| AVXL | DFAN14A | bullish | 7/10 | Activist investor PVG Asset Management, holding 337,663 shares of Anavex, announced that proxy advisor Glass Lewis recom | Sep 17, 2026 |
| ABT | PRESS-RELEASE | neutral | 2/10 | Abbott declared a quarterly common dividend of $0.63 per share, continuing its 411-quarter streak since 1924. The divide | Sep 17, 2026 |
| NVO | 6-K | bullish | 6/10 | Novo Nordisk announced that the EMA's CHMP has adopted a positive opinion recommending EU marketing authorization for FR | Sep 17, 2026 |
| LSTA | 8-K | bullish | 7/10 | Lisata Therapeutics (LSTA) has completed its acquisition of Marea Therapeutics via a reverse merger structured as a two- | Sep 17, 2026 |
| LSTA | PRESS-RELEASE | bullish | 7/10 | Lisata Therapeutics acquires Marea Therapeutics in a stock-for-stock transaction and concurrently raises $225 million in | Sep 17, 2026 |
| PHVS | CLUSTER | bearish | 5/10 | A cluster of insider sales at Pharvaris N.V. over the past week totaled approximately $2.41M in open-market sales, led b | Sep 17, 2026 |
| CELZ | PRESS-RELEASE | neutral | 2/10 | Creative Medical Technology Holdings filed a provisional patent application covering its Ultrasome cell-free regenerativ | Sep 17, 2026 |
| MIRA | 8-K | neutral | 4/10 | MIRA Pharmaceuticals announced that its Phase 2a protocol for Ketamir-2 in chemotherapy-induced peripheral neuropathy (C | Sep 17, 2026 |
| BIAF | 8-K | bullish | 4/10 | bioAffinity Technologies announced the Hong Kong Intellectual Property Department granted a patent (HK40048460) for its | Sep 17, 2026 |
| TELO | 8-K | neutral | 4/10 | Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data showing its lead compound Telomir-Zn | Sep 17, 2026 |
| SLGL | 6-K | neutral | 5/10 | Sol-Gel Technologies announced last patient last visit (LPLV) in its pivotal Phase 3 trial of SGT-610 (patidegib gel, 2% | Sep 17, 2026 |
| AAPG | 6-K | bearish | 5/10 | Ascentage Pharma reported H1 2026 results with revenue of RMB302.2M (+29.3% YoY), driven by product sales growth of 32.6 | Sep 17, 2026 |
| MIRA | PRESS-RELEASE | neutral | 3/10 | MIRA Pharmaceuticals announced submission of its Phase 2a protocol for Ketamir-2 in chemotherapy-induced peripheral neur | Sep 17, 2026 |
| TELO | PRESS-RELEASE | neutral | 4/10 | Telomir Pharmaceuticals published peer-reviewed preclinical data showing Telomir-Zn improved visual function and reduced | Sep 17, 2026 |
| QNTM | 6-K | neutral | 3/10 | Quantum BioPharma announced that Rodman & Renshaw initiated analyst coverage with a BUY rating and an $8 price target. T | Sep 17, 2026 |